ITF Therapeutics LLC — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
PROVIDUS — A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular DystrophyThis is a prospective observational study conducted to evaluate safety, tolerability, and functional outcomes of patients with DMD newly initiating oral givinostat or having started therapy within 6 months as part of routine clinical care in the US. The study has a planned maximum duration of 5 years for the first enrolled patients, including a 24-month enrollment period and a minimum of 2 years of follow-up.	Myopathies	À vérifier	À vérifier	United States	À vérifier
PROVIDUS — A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular DystrophyThis is a prospective observational study conducted to evaluate safety, tolerability, and functional outcomes of patients with DMD newly initiating oral givinostat or having started therapy within 6 months as part of routine clinical care in the US. The study has a planned maximum duration of 5 years for the first enrolled patients, including a 24-month enrollment period and a minimum of 2 years of follow-up.	Myopathies	À vérifier	À vérifier	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
PROVIDUS — A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy	Myopathies	À vérifier	NCT07127978	PROVIDUS — A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.